Induction and antagonism of antiviral responses in respiratory syncytial virus-infected pediatric airway epithelium.


Published in:
Journal of Virology

Document Version:
Peer reviewed version

Queen's University Belfast - Research Portal:
Link to publication record in Queen's University Belfast Research Portal

Publisher rights
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

General rights
Copyright for the publications made accessible via the Queen's University Belfast Research Portal is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The Research Portal is Queen's institutional repository that provides access to Queen's research output. Every effort has been made to ensure that content in the Research Portal does not infringe any person's rights, or applicable UK laws. If you discover content in the Research Portal that you believe breaches copyright or violates any law, please contact openaccess@qub.ac.uk.

Download date:09. Dec. 2018
Induction and antagonism of antiviral responses in respiratory syncytial virus-infected pediatric airway epithelium.

Rémi Villenave†1*, Lindsay Broadbent†1, Isobel Douglas2, Jeremy D. Lyons2, Peter V. Coyle3, Michael N. Teng4, Ralph A. Tripp5, Liam G. Heaney1, Michael D. Shields1,2, Ultan F. Power1#

1Centre for Infection & Immunity, School of Medicine, Dentistry & Biomedical Sciences, Queens University Belfast, Belfast BT9 7BL, Northern Ireland; 2The Royal Belfast Hospital for Sick Children, Belfast BT12 6BA, Northern Ireland and 3The Regional Virus Laboratory, Belfast Trust, Belfast, Belfast BT12 6BA, Northern Ireland; 4Joy McCann Culverhouse Airway Disease Research Center, Department of Internal Medicine, University of South Florida Morsani College of Medicine, Tampa, FL 33647, USA; 5Department of Infectious Diseases, University of Georgia, Athens, GA 30602, USA. *Current address: Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA 02215, USA.

†These authors contributed equally to this paper.

# Corresponding author: Ultan F. Power- Tel: 44.28.9097.2285- u.power@qub.ac.uk

Research article

Running title (50 characters): RSV and innate immunity in human airway epithelium

Abstract word count: 222

Text word count: 4139
Abstract

Airway epithelium is the primary target of many respiratory viruses. However, virus induction and antagonism of host responses by human airway epithelium remains poorly understood. To address this, we developed a model of respiratory syncytial virus (RSV) infection based on well-differentiated pediatric primary bronchial epithelial cell cultures (WD-PBECs) that mimics hallmarks of RSV disease in infants. RSV is the most important respiratory viral pathogen in young infants worldwide. We found that RSV induces a potent antiviral state in WD-PBECs that was mediated in part by secreted factors, including interferon lambda-1 (IFNλ1)/IL-29. In contrast, type I interferons were not detected following RSV infection of WD-PBECs., Interferon (IFN) responses in RSV-infected WD-PBECs reflected those in lower airway samples from RSV-hospitalized infants. In view of the prominence of IL-29, we determined whether recombinant IL-29 treatment of WD-PBECs before or after infection abrogated RSV replication. Interestingly, IL-29 demonstrated prophylactic, but not therapeutic, potential against RSV. The absence of therapeutic potential reflected effective RSV antagonism of IFN-mediated antiviral responses in infected cells. Our data are consistent with RSV non-structural proteins 1 and/or 2 perturbing the Jak-STAT signaling pathway, with concomitant reduced expression of antiviral effector molecules, such as MxA/B. Antagonism of Jak-STAT signaling was restricted to RSV-infected cells in WD-PBEC cultures. Importantly, our study provides the rationale to further explore IL-29 as a novel RSV prophylactic.

Importance

Most respiratory viruses target airway epithelium for infection and replication, which is central to causing disease. However, for most human viruses we have a poor understanding of their
interactions with human airway epithelium. Respiratory syncytial virus (RSV) is the most
important viral pathogen of young infants. To help understand RSV interactions with pediatric
airway epithelium, we previously developed 3-D primary cell cultures from infant bronchial
epithelium that reproduce several hallmarks of RSV infection in infants, indicating that they
represent authentic surrogates of RSV infection in infants. We found that RSV induced a potent
antiviral state in these cultures and that type III interferon (IL-29) was involved. Indeed, our data
suggest that IL-29 has potential to prevent RSV disease. However, we also demonstrated that RSV
efficiently circumvents this antiviral immune response and identified mechanisms by which this
may occur. Our study provides new insights into RSV interaction with pediatric airway epithelium.

Introduction

Airway epithelium is an extremely important barrier to respiratory pathogens. It is also the primary
infection target for many respiratory viruses. Elucidating the interactions between respiratory
viruses and airway epithelium is fundamental to understanding aspects of their pathogenesis. We
recently developed and characterized models of respiratory syncytial virus (RSV) infection based
on well-differentiated pediatric primary airway epithelial cells derived from pediatric bronchial
(WD-PBECs) or nasal (WD-PNECs) brushings (1, 2). RSV is the primary viral cause of infant
hospitalizations in the first year of life and is capable of repeated infections throughout life (3).
Despite its original isolation in 1957 (4), no effective RSV therapies or vaccines are available. The
mechanisms by which RSV causes disease and is capable of repeated infections in humans remain
an enigma. Our models reproduce several hallmarks of RSV infection \textit{in vivo}, suggesting that they
provide authentic surrogates with which to study RSV-induced innate immune responses and interaction with human airway epithelium (1, 2).

We previously reported secretion of high levels of CXCL10, an interferon-stimulated gene (ISG) product, from RSV-infected WD-PBECs (1, 2). This is consistent with the induction of an interferon (IFN)-mediated antiviral response to infection. IFNs are a heterogeneous family of cytokines with well characterized capacities to induce antiviral states in cells (5–7). They include types I (IFN-α/β), II (IFNγ) and III (IFNλs), only the first and last of which are expressed by airway epithelial cells upon appropriate stimulation (8–10). Despite considerable CXCL10 secretion, we detected no IFN-α/β secretion from RSV-infected WD-PBECs, while little or no IFN-α/β was detected in nasal or bronchoalveolar lavages from RSV-infected infants (1, 2, 11–13). In contrast, little is known about IFNλs responses to RSV infection of airway epithelium in vitro and especially in vivo. IFNλs comprise three closely related molecules designated IFNλ1 (IL-29), IFNλ2 (IL-28A) and IFNλ3 (IL-28B) (IFNλ2 and 3 share 96% identity) (14). They are induced by viruses, such as influenza A virus and rhinovirus, and inhibit replication of HCV and HIV. Interestingly, we and others recently demonstrated that IFNλs, rather than IFN-α/β, were induced following RSV infection of primary monolayer or well-differentiated nasal and bronchial epithelial cell cultures (2, 15). This suggested a role for IFNλs in RSV-induced antiviral responses. IFNλs induce antiviral states by signaling through a heterodimeric receptor complex composed of IL-28Ra and IL-10RA (14). This activates signal transduction through the Jak/STAT pathway in a manner that is virtually identical to IFN-α/β, resulting in phosphorylation of mainly signal transducer and activator of transcription (STAT)1 (pSTAT1) and STAT2 (pSTAT2) and, to a lesser extent, STAT3, 4 and 5. This is followed by pSTAT homo- or heterodimerisation, complexing with interferon regulatory
factor 9 (IRF9), nuclear translocation and induction of numerous ISGs, such as CXCL10 or the potent antiviral protein MxA (14, 16–18).

In the current study, we explored the induction of antiviral responses following RSV infection of WD-PBECs. We found that RSV induced a potent antiviral state against the related Sendai virus (SeV), which was mediated, in part at least, by secreted factors including IFNλ1/IL-29. We also demonstrated that RSV-induced IL-29 secretion from WD-PBECs reflected IL-29 secretions in lower airway samples from RSV-infected infants. These RSV-induced secreted factors also demonstrated prophylactic antiviral activity against RSV, albeit with lower potency than against SeV. Pre-treatment of WD-PBEC cultures with a high dose of IL-29 reduced RSV replication, suggesting the prophylactic potential of IL-29. Interestingly, RSV non-structural proteins NS1 and NS2, which we and others have previously shown to antagonize IFN-α/β-mediated antiviral responses (19–21), were critical for RSV growth in WD-PBECs and antagonism of IL-29-induced antiviral responses. We also found that in WD-PBECs, RSV-infected cells had significantly reduced MxA/B and pSTAT2 expression levels compared to surrounding non-infected cells, indicating active antagonism of antiviral responses by RSV but restriction of this antagonism to infected cells. In summary, our data provide novel insights into the induction and antagonism of antiviral responses, and in particular IL-29, following RSV infection of human airway epithelium.

Material and Methods.

Cell lines and viruses. HEp-2 and Vero cell lines were cultured as previously described (22). The origin and characterization of the clinical isolate RSV BT2a were previously described (23). Recombinant RSV expressing eGFP (rA2-eGFP) was generated by cloning a cassette consisting of
the eGFP ORF-NS1 gene end signal-NS1 gene start signal into an antigenomic cDNA (D53) of RSV at the position of the NS1 ATG. This scheme inserts an additional transcription unit encoding eGFP at the first position in the genome, preserving the RSV sequence from the leader through the NS1 5’ UTR. The eGFP containing D53 was then used to recover recombinant RSV in BSR-T7 cells as described (20, 24, 25). Production of recombinant RSV expressing eGFP in place of NS1 and NS2 (rA2-ΔNS1/2-eGFP) has been described (26). rA2-eGFP and rA2-ΔNS1/2-eGFP stock production and titrations were performed in Vero cells. Virus stocks were harvested and stored as previously described (27). Rescue, characterization, stock production and titration of rSeV/eGFP were previously described (22).

WD-PBEC culture and infection. WD-PBEC culture was described previously (28). Briefly, primary pediatric bronchial epithelial cells were obtained by bronchial brushings from healthy children undergoing elective surgery, expanded in culture flasks and seeded onto collagen-coated Transwell inserts (6.5 mm diameter, 0.4 µm pore size). Once confluence was reached, apical medium was removed to create an air-liquid interface (ALI) and trigger differentiation into pseudo-stratified mucociliary epithelium. Cultures were infected 3 to 4 weeks after ALI, as previously described (28), with multiplicities of infection (MOI) specified in the Figure legends. Virus stocks were diluted in DMEM where necessary. Inoculum or DMEM-only were added to the apical surface and cultures were incubated for 1.5 h at 37°C in 5% CO2 followed by 5 rinses with 500 µl DMEM. The last rinse was retained as the 2 h virus titration point. Every 24 h thereafter, apical rinses and basal medium were collected to determine virus growth kinetics and IFN responses, respectively. Infected and control cultures were monitored daily by light and UV microscopy, where appropriate (Nikon Eclipse TE-2000U). eGFP quantification in infected cultures was performed using ImageJ software (http://rsbweb.nih.gov/ij/).
Immunofluorescence, ELISA. Immunostaining of the cultures was previously described (28). Briefly, WD-PBECs were rinsed with PBS and fixed with 4% paraformaldehyde for 20 min. Cultures were washed and stored in PBS at 4°C until used. For immunofluorescence staining, cultures were permeabilized with PBS plus 0.2% Triton X-100 (v/v) for 2 h and blocked with 0.4% BSA (w/v) in PBS for 30 min. RSV-infected cells were detected using an anti-RSV F-specific mouse monoclonal antibody (MAb) (clone 133-1H conjugated with ALEXA 488, 1:200, Chemicon, US). MxA/B was detected using an anti-human Mx mouse MAb (Santa-Cruz, clone C-1, 1:200). pSTAT1 and pSTAT2 were detected using mouse anti-human pSTAT1 (pY701) MAb (BD Biosciences, 1:200) and rabbit anti-human pSTAT2 (Tyr690) polyclonal antibody (Antibodies-online, Inc, GA, USA; 1:200), respectively. The mouse anti-Mx and pSTAT1 (pY701) MAbs were detected with ALEXA-568-conjugated goat anti-mouse IgG1 (Invitrogen, 1:500), while rabbit polyclonal antibodies were detected with ALEXA-568-conjugated goat anti-rabbit IgG (H+L) (Invitrogen, 1:500) polyclonal antibodies, respectively. Inserts were mounted on microscopy slides and nuclei were counterstained using DAPI mounting medium (Vectashield). Fluorescence was detected by confocal laser scanning microscopy (TCS SP5, LEICA). MX and p-STAT fluorescence intensities were determined using confocal images of infected cultures in ImageJ by dividing the Raw Integrated Density by the area of each individual cell. This was done for >120 RSV-infected and non-infected cells.

IL-29 (IFN-λ1), pan-IFN-α and IFN-β concentrations in WD-PBEC basal media and in clinical samples were measured using human IFN-λ1 ELISA kits (eBioscience, UK), human IFN-β ELISA kits (R&D Systems), and human pan-IFN-α ELISA kits (Mabtech, Sweden). All ELISAs were undertaken according to the manufacturers’ instructions. IL-28A (IFN-λ2) was detected using a custom Milleplex kit, according to the manufacturer’s instructions (Merck-Millipore, UK).
Super-infection, conditioned medium and IFN-λ treatment. Super-infection experiments were undertaken by infecting WD-PBECs with RSV BT2a (MOI ≈ 4) for 72 h and super-infecting them with rSeV/eGFP (MOI ≈ 0.1), as described previously for 144 h (28). Conditioned medium (CM) experiments were performed by transferring basal medium from mock- (CMCON) or RSV-infected WD-PBECs cultures incubated with (CMRSV + αIL-29) or without (CMRSV) neutralizing antibody against IL-29 (R&D systems – MAB15981 - 10 µg/mL) at 72 hpi into the basal compartment of fresh cultures derived from the same individuals. Twenty four hours later conditioned cultures were infected with rSeV/eGFP. To assess anti-viral effects of IFN-λ1/IL-29 against RSV, rSeV/eGFP, rA2-eGFP and rA2-ΔNS1/2-eGFP, fresh WD-PBECs or Vero cells were treated before or after infection with IFN-λ1/IL-29 (Peprotech, UK). Antiviral effects were determined by measuring eGFP fluorescence and/or virus growth kinetics.

Lower airway sampling. Samples were obtained from 10 infants (mean age 0.31 years, range 0.06 -1.3 years) with severe RSV disease who were treated in the pediatric intensive care unit of the Royal Belfast Hospital for Sick Children. Samples were direct tracheobronchial aspirates or deeper suction samples following the instillation of 2 mL saline. All sampling was clinically indicated and not performed for research purposes. Fourteen uninfected and otherwise healthy children (mean age 1.7 years, range 1-2.4 years) acted as controls with blind non-bronchoscopic bronchoalveolar lavage samples obtained (after instillation of 10 mL saline) at the time of intubation for an elective surgical procedure (29). All RSV-infected infants were confirmed as having mono-infections using a multiplex virus reverse transcriptase (RT)-PCR strip for 12 respiratory viruses, as previously described (30).

Statistical analyses. Data obtained in vitro were described as mean [± SEM] and skewed data were log transformed before comparisons were made by Student’s paired t-test or by comparing the areas
under the curves using GraphpadPrism® 5.0. Data from RSV-infected and control children were compared using a Mann-Whitney t-test using GraphpadPrism® 5.0. $p < 0.05$ was considered statistically significant.

**Ethics.** This study was approved by The Office for Research Ethics Committees Northern Ireland (ORECNI). Written informed parental consent was obtained.

**Results**

**RSV infection induces an antiviral state in WD-PBECs.**

RSV infection of WD-PBECs generally occurred in non-contiguous or small clusters of ciliated epithelial cells (1, 2). This suggested the possibility that infection induced an anti-viral state in neighboring non-infected cells that limited viral spread. To detect the induction of antiviral responses we used rSeV/eGFP, as SeV replicates efficiently in WD-PBECs but is restricted in human cells pre-treated with human IFN (22, 28, 31). WD-PBECs (n=3 donors) were mock-infected or infected with RSV BT2a (MOI=4). Seventy-two h later, the cultures were super-infected with rSeV/eGFP (MOI=0.1). Fluorescence was monitored and apical washes were collected for virus titration every 24 h post-infection (hpi) with rSeV/eGFP for 144 h. Pre-infection with RSV potently inhibited rSeV/eGFP replication, as evidenced by greatly diminished eGFP expression and rSeV/eGFP growth kinetics (Fig. 1A-C). Thus, RSV infection induced a strong antiviral state in WD-PBECs.

**IFNλ1/IL-29 is the predominant interferon following RSV infection in-vivo and in-vitro.**
Previous work from us and others reported little or no IFN-α/β secretion following RSV infection of infants or airway epithelial cells in vitro (1, 32). In contrast, IL-29 was evident following RSV infection of primary airway (nasal) epithelial cells in vitro (2, 15). To confirm and extend these findings, we determined IFN-α/β, IL-28A and IL-29 concentrations in lower airway samples from infants hospitalized with severe RSV (n=8-10) and uninfected controls (n=11-14). Apart from one RSV-infected individual with low levels of IFNα, no IFN-α/β was detected in lower airway samples from infected infants (Fig. 2A and B). In contrast, IL-29 was significantly elevated in lower airway samples from RSV-infected patients compared to controls (Fig. 2C), although IL-28A was not (Fig. 2D). Furthermore, IL-29 concentrations in basolateral medium from RSV-infected WD-PBECs were significantly increased compared to controls and were similar to those in lower airway samples (Fig. 2E). Thus, our RSV/WD-PBEC model reproduced IL-29 responses to RSV infection in-vivo. Similarly, CM$_{RSV}$ from 2/5 RSV-infected WD-PBECs had only low levels of IL-28A at 96 hpi (Fig. 2F). The cumulative data suggest that IL-29 is an important IFN protagonist induced by RSV infection of infants and WD-PBECs and consequently might be responsible for the RSV-induced antiviral responses. Whether IFN-α/β are implicated in these antiviral responses, in contrast, is unlikely, although this remains to be definitively confirmed.

**Secreted factors, including IL-29, are implicated in the RSV-induced antiviral state.**

To determine if secreted factors, including IL-29, were implicated in the antiviral state induced in RSV-infected WD-PBECs, cultures (n=2-3 donors) were mock-infected or infected with RSV BT2a (MOI~1 or 4). At 72 hpi, CM$_{RSV}$ (with or without anti-IL-29 – 10 µg/mL) and CM$_{CON}$ were transferred to uninfected cultures derived from the same individuals. The cultures were infected 24 h later with rSeV/eGFP (MOI~0.1). eGFP expression (Fig. 3A, B) and rSeV/eGFP growth kinetics (Fig. 3C) indicated that factors secreted from RSV BT2a-infected WD-PBECs were responsible,
in part, for the RSV-induced antiviral effects. Importantly, when CM$_{RSV}$ was pre-incubated with
anti-IL-29 (CM$_{RSV} + \alpha$IL-29), the ability of CM$_{RSV}$ to abrogate rSeV/eGFP infection was
significantly reduced, suggesting an important role for IL-29 in the antiviral effect of CM$_{RSV}$.

**IL-29 attenuates rSeV/eGFP replication in WD-PBECs.**

To confirm that IL-29 has antiviral activities in airway epithelium, WD-PBECs (n=2-3 donors)
were pre-treated for 24 h with 100 or 1000 pg/mL IL-29 before infecting with rSeV/eGFP
(MOI~0.1). These concentrations represented high physiological and super-physiological
concentrations of IL-29, respectively, relative to IL-29 concentrations evident in CM$_{RSV}$ and lower
airway samples. IL-29 demonstrated a dose-dependent suppression of eGFP expression following
rSeV/eGFP infection, although both doses resulted in substantial reductions in eGFP expression
relative to controls (Fig. 4A, B). Furthermore, rSeV/eGFP growth kinetics were significantly
reduced following pre-treatment with both IL-29 doses (Fig. 4C), although these reductions, even
at the higher dose, were lower than those evident after CM$_{RSV}$ pre-treatment (Fig. 3C). The data
demonstrated that IL-29 has antiviral activities in airway epithelium and may account for some,
but not all, of the antiviral activity associated with CM$_{RSV}$.

**CM$_{RSV}$ and IL-29 prophylaxis attenuates RSV growth in WD-PBECs.**

To assess CM$_{RSV}$ antiviral activity against RSV, WD-PBECs cultures (n=2 donors) were mock-
infected or infected with RSV BT2a (MOI~4). At 72 hpi, CM$_{CON}$ and CM$_{RSV}$ were transferred to
uninfected cultures derived from the same individuals. CM-treated cultures were infected with rA2-
eGFP (MOI~0.1) 24 h later and fluorescence was monitored for 96 h (Fig. 5A). The eGFP
expression data demonstrated a similar, albeit lower, antiviral effect of CM$_{RSV}$ against RSV.
compared with rSeV/eGFP (Fig. 5A). This was also reflected in significantly reduced rA2-eGFP growth kinetics in CM<sub>RSV</sub>-treated compared to CM<sub>CON</sub>-treated WD-PBEC cultures (Fig. 5B).

To assess whether IL-29 had prophylactic or therapeutic potential against the clinical isolate RSV BT2a, cultures (n=3 donors) were untreated or treated with IL-29 for 24 h before infection (MOI~0.01) (1 ng/mL or 100 ng/mL), or at 2 or 24 hpi (100 ng/mL). Pre-treatment with 100 ng/mL IL-29 significantly reduced RSV replication (p<0.05), while pre-treatment with 1 ng/mL IL-29 did not (Fig. 5C). In contrast, IL-29 did not demonstrate therapeutic potential against RSV under our experimental conditions (Fig. 5D). The cumulative data from Figs. 3 and 5 suggested that RSV is more resistant to CM<sub>RSV</sub> and IL-29 than rSeV/eGFP, and that the antiviral activity of CM<sub>RSV</sub> against RSV in WD-PBECs is similar to that evident following pre-treatment with 100 ng/mL IL-29. In view of the considerably lower levels of IL-29 evident in CM<sub>RSV</sub> than those used in these experiments, IL-29 is unlikely to be solely responsible for the limited spread of RSV in WD-PBECs.

**RSV NS proteins antagonize IL-29-mediated anti-viral effects.**

The relative resistance of RSV to IL-29 suggested efficient antagonism of the IFNλ-signaling pathway in WD-PBECs. We and others have shown that RSV NS1 and particularly NS2 are responsible for antagonizing IFN-α/β signaling through degradation of pSTAT2 (19, 33). However, the capacity of RSV NS1/2 to antagonize IFNλ-mediated innate immune responses is unknown. To determine whether these proteins were implicated in antagonising IL-29-induced responses in WD-PBECs, cultures were initially infected with recombinant RSV expressing eGFP, either wild-type (rA2-eGFP) or lacking NS1 and NS2 (rA2-ΔNS1/2-eGFP) (MOI~0.1). While rA2-eGFP grew efficiently in WD-PBECs, replication of the NS1/2-deleted mutant was virtually abrogated (Fig.
6), indicating that NS1 and/or NS2 were critical for RSV replication in WD-PBECs. This result precluded the use of WD-PBECs to address antagonism of IL-29-mediated antiviral responses by RSV. As both the mutant and wild type viruses grew efficiently in Vero cells and these cells were sensitive to IFNλs stimulation (34, 35), we addressed the role of RSV NS1/2 in IL-29 antagonism in Vero cells. The cells were pre-treated with IL-29 (1 or 100 ng/ml) or mock-treated for 24 h before infection with either rA2-eGFP or rA2-ΔNS1/2-EGFP (MOI~0.1). Treated and control cultures were subsequently incubated for 72 h in the presence and absence of IL-29, respectively. Pre-treatment with 1 ng/mL IL-29 had no effect on rA2-eGFP replication, as indicated by eGFP expression kinetics, while 100 ng/mL did (Fig. 7A, C). By comparison, pre-treatment with either dose of IL-29 had much more dramatic effects on rA2-ΔNS1/2-eGFP replication than rA2-eGFP (Fig. 7B, D). Thus, RSV NS1/2 proteins are implicated in antagonizing IL-29-mediated antiviral responses.

**RSV antagonizes pSTAT2 and MxA/B expression in WD-PBECs.**

To gain insight into the mechanisms behind RSV antagonism of the antiviral responses induced in WD-PBECs, we looked at the capacity of RSV to antagonize Jak/STAT signalling and MxA/B expression on a single cell basis within individual infected and surrounding non-infected cells. As MxA/B expression is a reliable marker of IFN bioactivity (36), we initially confirmed that RSV infection, IL-29 treatment, or CM RSV treatment induced MxA/B expression in WD-PBECs (Fig. 8A and B). Furthermore, when CM RSV was pre-treated with anti-IL-29, MxA/B expression was virtually abrogated, demonstrating that MxA/B induction following CM RSV-treatment was in large part mediated by IL-29 (Fig. 8B and C). We and others previously reported that RSV NS proteins block the IFNα/β-stimulated Jak/STAT signalling pathway by targeting pSTAT2 for proteasomal degradation (19, 37). To study RSV antagonism of Jak/STAT signalling and MxA/B expression in
WD-PBECs, cultures (n=3-4 donors) were infected with RSV (MOI~0.1), subjected to daily apical rinses and basolateral medium change, fixed, permeabilized and co-stained for RSV F and either pSTAT1, pSTAT2 or MxA/B at 144 hpi (Fig. 9A-F). pSTAT1 fluorescence intensities were similar in both infected and non-infected cells (Fig. 9E, F). In contrast, pSTAT2 protein was significantly diminished (Fig. 9C, D), while MxA/B proteins were virtually absent (Fig. 9A, B), in RSV-infected compared to surrounding non-infected cells. Thus, antagonism of the RSV-induced IFN-mediated antiviral responses was restricted to infected cells and implicated the perturbation of the Jak/STAT signalling pathway by pSTAT2 down-regulation.

Discussion

Innate immune responses are critical first lines of defense against virus infection (38, 39). The capacity for viruses to antagonize or circumvent these responses is essential for their successful replication. Our RSV/WD-PBEC model provided a unique opportunity to study the induction and antagonism of innate antiviral immune responses by RSV in a morphologically- and physiologically-authentic model of pediatric bronchial epithelium. We exploited the fact that RSV infection does not lead to gross destruction of WD-PBECs to establish super-infection experiments with rSeV/eGFP. rSeV/eGFP was particularly useful for these experiments as it replicates very efficiently in untreated WD-PBECs but is sensitive to human IFN (28, 31). These characteristics provided the unique opportunity to establish a novel bioassay to study RSV-induced antiviral responses in WD-PBECs based on SeV-derived eGFP expression and SeV growth kinetics.

Our rSeV/eGFP super-infection bioassay unambiguously demonstrated that RSV induced a potent antiviral response in WD-PBECs and that basolaterally-secreted factors were, in part, responsible for this anti-viral activity. Importantly, IFN-λs, particularly IL-29, but not IFN-α/β, were detected
in RSV-infected WD-PBECs. This is consistent with Okabayashi et al (2011), who showed a
predominance of IL-29 secretion from RSV-infected primary and immortalized nasal epithelial cell
monolayers (15). A major finding of our study is the preponderance of IL-29 and the absence of
detectable IFN-α/β in lower airway samples from RSV-infected infants, suggesting that IFN-λs,
and in particular IL-29, are the principal interferons responding to RSV infection in vitro and in
vivo. The lack of detectable IFN-α/β in CM<sub>RSV</sub>, as reported previously (1), and in lower airway
samples from infants hospitalized with RSV, as reported here, is consistent with earlier clinical
observations (11–13). It is unclear whether this lack of detectable IFN-α/β in CM<sub>RSV</sub> is due to a
failure to stimulate these responses and/or active antagonism of induction by RSV NS1/2. Indeed,
using immortalized cell lines, RSV NS proteins were shown to antagonize IFNα/β induction by
interacting with RIG-I, disrupting association of IRF-3 with CBP and, thereby, IRF-3 binding to
the IFN-β promoter, and suppressing activation and nuclear translocation of IRF-3 (19, 40, 41).
They also antagonized IFNα/β signaling by inducing proteasome-mediated degradation of pSTAT2
(19, 37). Additionally, RSV NS1, and to a lesser extent NS2, were shown to decrease cellular
levels of TRAF3 and IKKe, both key members of the IFN response pathway (42). However, Killip
et al recently demonstrated that even when viral IFNα/β antagonists were deleted, the
paramyxovirus PIV5 failed to activate the IFNβ promoter, suggesting that members of the
Paramyxoviridae are very inefficient at inducing IFN-α/β responses (43). The corollary, however,
is that the IFN antagonistic capacities of these viruses likely evolved to cope with IFN-λs, rather
than IFN-α/β, responses.

Therefore, we evaluated the capacity of RSV NS1/2 to antagonize IFN-λ1/IL-29-mediated antiviral
effects. We demonstrated that NS1 and/or NS2 were essential for RSV resistance to IL-29-
mediated antiviral activity in Vero cells and for replication of RSV in WD-PBECs. At a cellular
level in WD-PBECs, we showed that RSV infection inhibited the interferon-inducible Jak/STAT pathway through p-STAT2 suppression, with concomitant reduction of the expression of the IFN-induced antiviral GTPases, MxA/B (18). However, this inhibition in WD-PBECs was restricted to infected cells. As MxA/B are reliable markers of IFN bioactivity and IL-29 was the only IFN detected in CM_{RSV}, our cumulative data are consistent with a model in which RSV infection induces IL-29-mediated antiviral activity in WD-PBECs but that RSV NS1/2 proteins efficiently antagonize these responses only in infected cells through pSTAT2 degradation. Although IFNα/β were not detected in our assays, the possibility remains that very low biologically active levels were present. Further work is therefore needed to definitively exclude their role in RSV-induced antiviral responses in WD-PBECs.

There is an increasing body of evidence confirming the capacity of IL-29 to induce antiviral states in infected cells (5, 8, 44). Our data extend this IL-29 capacity to SeV and RSV. We found no evidence that IL-29 has therapeutic potential against RSV infection. However, we present evidence that IL-29 has prophylactic potential against RSV, as demonstrated by retarded RSV growth kinetics in IL-29 pre-treated WD-PBECs compared with untreated controls. These data provide the rationale for further studies on IL-29 prophylaxis to modulate RSV pathogenesis. This is of particular interest for individuals at risk for severe illness due to RSV infection, although more work is needed to better understand IL-29 responses \textit{in vivo}. Moreover, the IL-29-mediated antiviral effects against RSV, combined with the tissue-restriction of the type III IFN receptor to epithelial cells, the liver and some leukocytes suggest that IL-29 prophylaxis may result in limited toxicities that are typical of type I IFN therapy (45). Indeed, early data from clinical trials using IFN-λ to treat chronic hepatitis C virus support this possibility (46).
Our evidence suggests the exciting prospect of potentially novel potent antiviral molecules in CM\textsubscript{RSV} that are not explained by its IL-29 content alone. Neutralizing IL-29 eliminated a large portion of the antiviral activity of CM\textsubscript{RSV}. However, CM\textsubscript{RSV} demonstrated greater antiviral potency than 1 ng/mL recombinant IL-29, which represents ~25 fold increase relative to the mean IL-29 concentration in CM\textsubscript{RSV}. Therefore, it is possible that other molecules in CM\textsubscript{RSV} act in synergy with IL-29 to exert its impressive antiviral activities. Indeed, such synergistic antiviral activity was previously reported for IFN\textalpha/\beta and INF\gamma against herpes simplex virus 1 (HSV-1), hepatitis C virus (HCV) and severe acute respiratory syndrome-associated coronavirus (SARS-CoV)(47–49). However, further work is required to identify such molecules and determine whether such synergy is evident in our WD-PBEC model.

Finally, there is increasing molecular diagnostic evidence demonstrating concomitant dual or multiple respiratory viral infections in individuals (50, 51). Debate is ongoing as to whether such dual/multi-infections result in exacerbated disease compared with mono-infections. Extrapolation of our data to the clinic suggests that a primary infection with RSV would result in the induction of an antiviral state in the airway epithelium that may greatly compromise the capacity of subsequent viruses to infect and replicate, unless the second virus was adept at circumventing the pre-established innate immune responses. This is consistent with a recent study showing that infection with multiple respiratory viruses correlated with less severe disease (52).

In conclusion, our study significantly advances our understanding of RSV induction and antagonism of type III IFN responses in human airway epithelium. Importantly, it provides the rationale for dissecting the molecular mechanisms by which these occur and the possible exploitation of IL-29 as a novel RSV prophylactic, either alone or in combination with other yet-to-be discovered CM\textsubscript{RSV} antiviral molecules.
Acknowledgments

We are most grateful to the children and parents who consented to participate in this study. Funding was provided by the Public Health Agency HSC Research & Development Division, Northern Ireland, the European Social Fund, Northern Ireland Chest Heart and Stroke, and the Royal Belfast Hospital for Sick Children. MNT thanks Peter Collins (NIAID) for the use of the RSV reverse genetics system.

References


**Figure Legends.**

**Figure 1. Pre-infection of WD-PBECs with RSV induces an anti-viral effect.** WD-PBECs (n = 3 donors) were mock-infected or infected with RSV BT2a (MOI~4). Seventy two hpi, RSV- and mock-infected cultures were super-infected with rSeV/eGFP (MOI~0.1). (A) RSV-infected and mock-infected cultures were monitored by UV microscopy every 24 h (original magnification, x4). These photos are representative of duplicate cultures from 3 individual donors. (B) eGFP expression was quantified every 24 h by measuring the % of green pixels in 3 different microscope fields. (C) Virus growth kinetics was determined by titrating rSeV/eGFP in apical washes at 24 h intervals following infection. Data are presented as mean ± SEM log_{10} fluorescent focus units (ffu)/mL.

**Figure 2. Type III IFN, but not type I IFN, is detected following RSV infection in-vivo and in-vitro.** Lower airway samples from infants hospitalized for severe RSV infection (n=10 donors) and healthy controls (n=14 donors) were analyzed for pan-IFN-α (A), IFN-β (B), IL-29 (C) or IL-28A (D) by ELISA. Data are presented as mean ± SEM. Statistical analyses were undertaken using a non-parametric t-test followed by a Mann-Whitney test. ***p = 0.0005. WD-PBECs (n=5 donors) were infected with RSV (MOI~4). IL-29 (E) or IL-28A (F) secretions in the basolateral medium of RSV- and mock-infected cultures harvested at 24 and 96 hpi were measured. As the medium was replaced every day, the data correspond to IFN secretions within the preceding 24 h. Values are means ± SEM. **p<0.01.

**Figure 3. RSV-induced antiviral effect is partially mediated by IL-29.** WD-PBECs (n=2-4 donors) were infected with RSV BT2a (MOI~4) or mock infected. Seventy two hpi, the basal medium of mock- (CM_{CON}) or RSV-infected cultures incubated with (CM_{RSV} + αIL-29) or without
(CM<sub>RSV</sub>) neutralizing antibody against IL-29 (10 µg/mL) was transferred into the basal compartment of fresh cultures from the same individual donor. Twenty four h later, the cultures were infected with rSeV/eGFP (MOI~0.1). (A) eGFP expression in CM<sub>CON</sub>-, CM<sub>RSV</sub> + αIL-29- and CM<sub>RSV</sub>-treated rSeV/eGFP-infected WD-PBECs over time (original magnification x4). (B) eGFP expression was quantified every 24 h by measuring the % green pixels in 5 random microscopic fields. (C) Virus growth kinetics were determined by titrating rSeV/eGFP in apical washes at 24 h intervals following infection. Data are presented as mean ± SEM log<sub>10</sub> ffu/mL. Area under the curves were calculated and compared using an unpaired Student’s t-test. **p < 0.01; ***p < 0.001.

**Figure 4. Influence of IL-29 pre-treatment on rSeV/eGFP growth in WD-PBECs.** WD-PBECs (n=3 donors) were pre-treated with IL-29 (100 pg/mL and 1000 pg/mL) or mock-treated. Twenty four h later, cultures were infected with rSeV/eGFP at an MOI~0.1. UV microphotographs were taken every 24 hpi (A). Original magnification, x4. eGFP expression was quantified every 24 hpi by measuring the % green pixels in 3 random microscopic fields (B). Virus growth kinetics were determined by titrating rSeV/eGFP in apical washes at 24 h intervals following infection (C). Data are presented as mean ± SEM log<sub>10</sub> ffu/mL. Area under the curves were calculated and compared using an unpaired Student’s t-test. *p<0.05.

**Figure 5. CM<sub>RSV</sub> and IL-29 pre-treatment attenuates RSV growth in WD-PBECs.** WD-PBECs (n=2 donors) were infected in duplicate with RSV BT2a (MOI~4) or mock infected. Seventy two hpi, the basal medium of mock- (CM<sub>CON</sub>) or RSV-infected cultures (CM<sub>RSV</sub>) was transferred into the basal compartment of fresh cultures from the same individual donor. Twenty four h later, the cultures were infected with rA2-eGFP (MOI~0.1). eGFP expression was quantified every 24 h by measuring the % green pixels in 3 different microscopic fields (A). Virus growth
kinetics were determined by titrating rA2-eGFP in apical washes at 24 h intervals following infection (B). WD-PBECs (n=2-3 donors) were pre-treated with IL-29 (1 or 100 ng/mL). Twenty four h later, cultures were infected with RSV BT2a at an MOI~0.01 (C). WD-PBECs (n=3 donors) were infected with RSV BT2a at an MOI of 0.01. Two or 24 hpi, infected cultures were treated with IL-29 (100 ng/mL) (D). Virus growth kinetics was determined by titrating RSV in apical washes every 24 h following infection for (C) and (D). Data are presented as mean + SEM log_{10} TCID_{50}/mL. Area under the curves were calculated and compared using an unpaired Student’s t-test. *p < 0.05, **p < 0.01.

Figure 6. rA2-ΔNS1/2-eGFP does not infect efficiently WD-PBECs. WD-PBEC cultures were infected in duplicate with either rA2-eGFP or rA2-ΔNS1/2-eGFP (MOI~1) for 96 h. Representative fluorescence pictures were taken at 96 hpi (A). rA2-eGFP or rA2-ΔNS1/2-eGFP titers at 96 hpi were measured (B). Data are presented as mean ± SEM log_{10} TCID_{50}/mL. *** p < 0.001.

Figure 7. RSV NS1/2 partially counteract IL-29-mediated anti-viral effects. Vero cells were pre-treated with IL-29 (1 or 100 ng/mL) or non-treated. Twenty four h post treatment, the cells were infected with rA2-eGFP (A) or rA2-ΔNS1/2-eGFP (B) (MOI=0.1). Cultures were monitored by UV microscopy every 24 hpi (original magnification, x4). Infections were undertaken in triplicate and a surrogate for virus replication kinetics was quantified by measuring % eGFP coverage of 3-5 microscope fields at each time point (C, D). Data are presented as mean ± SEM eGFP area (% whole image) and are representative of three independent experiments in triplicate. Area under the curves were calculated and compared using an unpaired Student’s t-test. ***p < 0.001.
**Figure 8.** MxA/B expression is induced following RSV infection, and IL-29 or CM<sub>RSV</sub> treatment of WD-PBECs. (A) WD-PBECs were either mock-infected, RSV BT2a-infected (MOI ~0.1) for 96 h, or treated with IL-29 (1 ng/mL) for 24 h. Cultures were fixed and stained for MxA/B (red) and nuclei were counter-stained with DAPI (blue). Confocal images show typical staining in WD-PBECs from 3 individual donors. (original magnification, x63). (B) and (C) MxA/B expression following treatment with CM<sub>RSV</sub> is mediated in large part by IL-29. WD-PBECs (2 independent cultures from 1 donor) were incubated with either CM<sub>RSV</sub> or CM<sub>CON</sub> alone or combined with a neutralizing antibody against IL-29 (10 µg/mL) for 24 h. Cultures were fixed and stained for MxA/B and nuclei were counter-stained with DAPI. The MxA/B signal was quantified in 5 individual fields from each culture, and mean fluorescence was calculated and plotted. **p<0.01, ***p<0.001.

**Figure 9.** RSV blocks the expression of MxA/B, p-STAT2 but not p-STAT1 in infected WD-PBECs. WD-PBECs were either mock- or RSV-infected (MOI~0.1) for 96 h. Cultures were fixed and either stained for (A) MxA/B, (C) p-STAT1 or (E) p-STAT2 (red); RSV was detected using a FITC-conjugated anti-RSV-F-specific antibody (green). Confocal images show typical staining from WD-PBECs derived from 3 different individual donors (original magnification, x63). Fluorescence of MxA/B (B), p-STAT1 (D) and p-STAT2 (F) in RSV-infected and uninfected cells within RSV-infected WD-PBEC cultures was quantified by dividing the Raw Integrated Density by the Area of >120 individual cells. Fluorescence was quantified using ImageJ software. Data are presented as mean ± SEM. ***p < 0.0005.
Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

A. eGFP area (% whole image)

B. A20-eGFP assay (log10 PRU/mg)

C. RSV titre 1:100 TCD50/ml

D. RSV titre 1:100 TCD50/ml
Fig. 6
Fig. 7

A  rA2-eGFP

B  ΔNS1/2-eGFP

<table>
<thead>
<tr>
<th></th>
<th>NT</th>
<th>IL-29 1 ng/mL</th>
<th>IL-29 100 ng/mL</th>
</tr>
</thead>
<tbody>
<tr>
<td>24h</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>48h</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>72h</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

C  Non treated

D  Non treated